View Online
January 10, 2020
News From Medscape
The following recommended articles on are freely available through the partnership between ABC and Medscape, no registration or login required.
Advice Doctors Wish They Had Gotten During Med School
The clarity of hindsight about medical school allows senior physicians to reflect on their training and think, "If only I had known then what I know now." Medscape's medical student advisory board was asked to provide the next generation of physicians with the advice they wish they had been given back then.
European Left Main Guidelines in Disarray After EXCEL Cover-up Alleged
The European Association for Cardio-Thoracic Surgery (EACTS) has withdrawn support for its left main coronary artery disease recommendations following an exposé by BBC Newsnight alleging key data from the EXCEL trial were concealed.
FDA Approves Amarin's Vascepa for Cardiovascular Risk Reduction
The Food and Drug Administration (FDA) has approved icosapent ethyl (Vascepa, Amarin) to reduce the risk for cardiovascular (CV) events in people with elevated triglyceride levels and either established CV disease or diabetes with other CV risk factors, the agency announced last month.
Women Make Up the Majority of US Med Students for First Time
This year, for the first time, more women than men are enrolled as US medical students, according to the Association of American Medical Colleges (AAMC). This progress builds on a milestone reached in 2017, when, for the first time, women comprised the majority of first-year medical students, as reported previously by Medscape Medical News.
Items of Interest
How Community Health Workers Can Help Improve Outcomes, Cut Costs
Some may ask whether a community health worker—a person in the community to whom patients can go to for help, support and informal counseling—is new. The truth, though, is that it has existed for generations across the globe and in many different cultures. During an event at the AMA’s Chicago headquarters, guest speaker Sergio Matos—founder of the National Association of Community Health Workers—spoke with Diana Derige, director of strategy and development in the AMA Center for Health Equity. They discussed how physicians and health systems can develop effective partnerships with CHWs to advance the quadruple aim without overmedicalizing a critical community role.
Expression and Outcomes of Hypertrophic Cardiomyopathy in Black and White Patients
Hypertrophic cardiomyopathy in black vs white patients may be associated with a greater burden of functional heart failure and reduced access to care and genetic testing, according to a study published in JAMA Cardiology. In this retrospective cohort study, researchers assessed data on black and white patients with HCM who were evaluated between 1989 and 2018 at 7 US sites that participated in the Sarcomeric Human Cardiomyopathy Registry.
Genetic Breakthrough Identifies Heart Failure Risk in African and Latino Americans
A genetic variation believed to increase risk for heart failure in people of African or Latino ancestry has been identified in a new study by researchers from the Icahn School of Medicine at Mount Sinai and Perelman School of Medicine at the University of Pennsylvania. The study found that the transthyretin or TTR V122I genetic variant was significantly associated with heart failure and that heredity transthyretin amyloid cardiomyopathy (hATTR-CM) caused by this variant was confirmed at appreciable frequency in individuals of African or Latino ancestry. The results suggest a significant under-recognition and under-diagnosis of this potentially fatal disease.
Farxiga Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction
AstraZeneca recently announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). Farxiga is a first-in-class, oral once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2).
Sanofi and Regeneron Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) by restructuring into a royalty-based agreement. Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.
Welcome ABC Research Coordinator, Uzoma C Onukwubiri, MPH!

The Association of Black Cardiologists is delighted to welcome Uzoma C. Onukwubiri as its new Clinical Research Coordinator. Uzoma will work collaboratively with the Research Committee, Chief Science Officer and ABC investigators to engage in the broad breadth of research activities that are underway and under consideration at the ABC.

Prior to joining ABC, Uzoma served as Clinical Data Manager for the National Cancer Institute. She earned her undergraduate degree in Life Sciences at Pennsylvania State University. While at Penn State, Uzoma volunteered as a Health Educator with Shomeka Outreach, a nonprofit organization dedicated to promoting sustainable maternal health in remote areas of Zambia. She received a Masters in Public Health with a concentration in Human Genetics from the University of Pittsburgh. Uzoma also completed her graduate practicum on “Factors Contributing to Oral Health Disparities in Appalachia” at the University of Pittsburgh School of Dental Medicine where she was a Research Assistant.

During her spare time, Uzoma loves to travel.

Featured Articles by Members
ABC Members: We welcome your published research submissions and articles for inclusion in future issues of Clinical Updates and Insights. Email Rachel Williams at and please attach file or include links to the original published work and/or abstract.
Contemporary Utilization Patterns And Outcomes of Thrombolytic Administration For Ischemic Stroke Among Patients With Cancer
Co-authored by Daniel Addison (with Jocelyn Owusu-Guha, Avirup Guha, P. Elliott Miller, Sumeet Pawar, Amit K. Dey, Tariq Ahmad, Hatim Attar, Farrukh T. Awan, Darrion Mitchell, and Nihar R. Desai)
Thrombolytic therapy significantly improves outcomes among patients with acute ischemic stroke. While cancer outcomes have dramatically improved, the utilization, safety, and mortality outcomes of patients with cancer who receive thrombolytic therapy for acute ischemic stroke are unknown. Using a national database, trends in thrombolytic therapy use and its effect on in-hospital mortality, intracranial or all-cause bleeding, and the combined endpoint of mortality and all-cause bleeding, by presence/absence of cancer were evaluated.
Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease [Insights From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial]
Co-authored by Renee P. Bullock-Palmer, MD (with Angela Lowenstern, MD; Karen P. Alexander, MD; C. Larry Hill, PhD; Brooke Alhanti, PhD; Patricia A. Pellikka, MD; Michael G. Nanna, MD; Rajendra H. Mehta, MD; Lawton S. Cooper, MD; et al.)
Although cardiovascular (CV) disease represents the leading cause of morbidity and mortality that increases with age, the best noninvasive test to identify older patients at risk for CV events remains unknown. This study sought to determine whether the prognostic utility of anatomic vs functional testing varies based on patient age.

We LOVE to LEARN how our ABC Members are making a difference! Please Share. Giving a keynote speech? Presenting at a Grand Round? Receiving an Award? Interviewed by the Press? Published in a journal? Presenter or Panelist at a Conference? Graduating? Email Rachel Williams at or please tag or DM us on Facebook, Twitter or Instagram with links/details, so we can spotlight your excellence in our newsletter!


Call For Applications:
Course Director of ACC CV Overview and Board Review Course

The ACC is seeking a qualified candidate to serve as course director for the ACC Cardiovascular Board Review and Overview Course – taking place Sept. 7-12, 2020, in Washington, DC.

The commitment will be for a one-year term and the new course director will work in collaboration with the current course director, Patrick T. O'Gara, MD, MACC, and ACC staff to develop the educational course, and in selecting and preparing the faculty team.

Interested candidates are encouraged to review the position description and complete the application form. A cover letter highlighting credentials as well as a curriculum vitae should be submitted along with the application.

The Lifelong Learning Oversight Committee is responsible for reviewing applications and will determine final selection of the Course Director.

Completed materials should be submitted to Camille Haynes at, on or before midnight on Friday, Jan. 17. There will be no extensions to the deadline for applications.


ABC's Dr. Jay Brown Best Abstract Competition

Submit your abstract summarizing any problem that relates to cardiovascular disease whether it is: Clinical, Basic or Population Science. Abstract must be original scientific research and must not have been published previously.

Any physician/scientist presently in a residency or cardiology fellowship training program and active in the Association of Black Cardiologists is eligible.

Four (4) outstanding abstracts will be selected for presentation at ABC's Annual Fellows Program on Friday, March 27, 2020 at the Hilton Chicago in Chicago, IL.

The winner of the Dr. Jay Brown Best Abstract Competition will also receive a $1,000 cash award.

Deadline to submit your abstract is February 7, 2020.


Upcoming Events

This email was sent to ##email## by Association of Black Cardiologists, powered by Powered by Multiview's Content Marketing
Archive | View Online | Unsubscribe | Subscribe